Format

Send to

Choose Destination
Mol Diagn Ther. 2016 Apr;20(2):111-7. doi: 10.1007/s40291-016-0192-5.

Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy.

Author information

1
Department of Specialistic Clinical and Odontostomatological Sciences, Polytechnic University of Marche Region, 60131, Ancona, Italy. f.piva@univpm.it.
2
Department of Specialistic Clinical and Odontostomatological Sciences, Polytechnic University of Marche Region, 60131, Ancona, Italy.
3
Clinica di Oncologia Medica, AOU Ospedali Riuniti, Università Politecnica delle Marche, via Conca 71, 60126, Ancona, Italy.
4
Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Italy.
5
Department of Pathology and Surgery, Faculty of Medicine, University of Cordoba, Cordoba, Spain.
6
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.

Abstract

Epithelial-to-mesenchymal transition (EMT) is a developmentally vital reversible process by which fully differentiated cells lose their epithelial features and acquire a migratory mesenchymal phenotype. EMT contributes to the metastatic potential of tumors. The expression profile and other biological properties of EMT suggest potential targets for cancer therapy, including in renal-cell carcinoma (RCC). The preclinical and clinical results have substantiated the promises that dysregulated elements leading to EMT can be a potential target in RCC patients. In this study, we illustrated the pathogenic and prognostic role of EMT in RCC. In addition, we reconstructed, by literature analysis, the different pathways implicated in the EMT process, thus supporting the rational for future EMT-directed therapeutic approaches for RCC patients.

PMID:
26940073
DOI:
10.1007/s40291-016-0192-5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center